Elixion’s R&D approach

A unique R&D approach engineered for precision

Elixion is the only company applying quantum physics, causal biology, multi-omics and native AI across its entire R&D process.

Developed exclusively for our own and carefully chosen co-development programmes, Elixion’s R&D approach provides the following clear advantages:

  • Quantum physics-informed target identification – increases the precision and speed of discovery.
  • Atomic-level modelling of molecular interactions – improves drug design with earlier and more reliable predictions of efficacy, toxicity and stability.
  • Quantum-informed AI investigation and engineering – reveals novel molecules, previously invisible to traditional scientific approaches.

Better prediction = fewer failures = shorter development cycles = costs savings

Not SaaS. Not commoditised. A unique R&D approach built for internal scale and strategic exclusivity.

  • «The convergence of quantum physics and native AI in drug development enables us to tackle the toughest challenges in therapeutics, driving innovation where others see boundaries. Our unique R&D approach enhances precision across our own ambitious disease programmes, ensuring that every breakthrough directly advances our mission.»
    Carla Carvalho, PhD, Eng
    Chief Data Officer & Co-Founder